Median OS and EFS were 7.5 months (95% CI, 3.5–15.4) and 6.2 months (95% CI, 3.5–13.2) for the “TP53/PPM1D” subgroup, 14.5 (95% CI, 7.5–41.5) and 10.6 (95% CI, 7.5–41.5) for the “MDS-like” subgroup, and 25.2 (95% CI, 13.3–NR) and 18.4 (95% CI, 7.1–NR) months for the “de novo/pan-AML” subgroup, respectively (P < 0.001) (Figure 2C). This evidence concerns the gene TP53 and myelodysplastic syndrome.